The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / October / A Night Shift for IOP
Glaucoma Research & Innovations News

A Night Shift for IOP

Researchers uncover a molecular pathway that may drive nocturnal IOP elevation, revealing potential new target for glaucoma chronotherapy

10/9/2026 3 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll
5 Key Takeaways
  • 1

    Norepinephrine increased RHOB expression and activity in mouse eyes and human trabecular meshwork cells through β1-adrenergic receptor–cAMP–CREB signaling.

  • 2

    RHOB deficiency enhanced trabecular meshwork cell phagocytosis, whereas RHOB overexpression suppressed phagocytosis and reduced cell-layer permeability.

  • 3

    The findings support a model in which nocturnal norepinephrine signaling increases RHOB activity, suppresses phagocytosis, and may raise aqueous outflow resistance and nighttime IOP.

  • 4

    In mice, RHO and ROCK inhibitors suppressed nocturnal IOP elevation and prevented the IOP increase induced by the β1-adrenergic agonist dobutamine.

  • 5

    The study relied heavily on cultured cells and male mice, and the authors noted that circadian norepinephrine release from the superior cervical ganglion has not been clearly established in humans.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: